Practical implication
Update labeling and monitoring protocols to include new prescribing information, dosage guidelines, and risk communications related to the potential cardiac risks associated with camizestrant.
On September 4, 2026, the FDA granted accelerated approval to camizestrant (Etcamah) as a treatment for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with detectable ESR1 mutations, alongside a CDK4/6 inhibitor. This approval includes the Guardant360 CDx assay as a companion diagnostic.
What changed: The FDA has granted accelerated approval for camizestrant, prompting the need for updates to labeling, prescribing information, and risk communications regarding its use and associated warnings.
Why it matters: The approval of camizestrant offers a new treatment option for a specific breast cancer subtype, potentially improving patient outcomes through tailored therapy based on genetic markers.
Practical implication: Update labeling and monitoring protocols to include new prescribing information, dosage guidelines, and risk communications related to the potential cardiac risks associated with camizestrant.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-09-04T00:00:00.000Z
- Discovered by monitor: 2026-09-04T21:35:40.441Z
Published from the regulator source ingestion pipeline after PV impact triage.
